JACKSON CENTER, Pa., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Premier Biomedical, Inc. (OTC:BIEI) President and CEO, William A. Hartman was interviewed by host, Ken Evseroff, on the program “New To The Street”, which aired on the Fox Business Channel on Sunday, January 28, 2018. In the segment, Mr. Hartman provided background on the origins of the company and its current direction. With the company’s new product line of topical pain relief products, it hopes to capture a significant portion of that multi-billion dollar annual sales market.
Mr. Hartman also stressed the absence of THC or other psychoactive ingredients in Premier Biomedical’s products and the value of these products as an alternative to dangerously addictive opioids for the treatment of pain. You can view the video here.
For more information please contact:
William A. Hartman
President and CEO
Premier Biomedical, Inc.
Pain Relief Meds
(724) 633-7033
w.hartman@premierbiomedical.com
www.premierbiomedical.com/
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTC:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI." For more information please visit our website: http://www.premierbiomedical.com/.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.